2025 Annual Meeting | C109 - Core Concepts in Pain Management: Safe and Appropriate Opioid Prescribing in Neurology

Date Monday 04/07/25

Time 01:00 PM - 03:00 PM PDT Add To Calendar

Location San Diego Convention Center | 29B

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Nicholas J. Silvestri, MD, FAAN

Topic(s) Pain

Learning Objectives Participants should understand the principles and challenges behind the management of neuropathic pain related to peripheral nervous system disorders; the cascade of neuropathic pain mechanisms, the rationality of combination therapy to address different mechanisms of action, and costs related to opiate use and painful diabetic neuropathy; and pharmacological and alternative approaches in managing these challenging patient issues.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Professionalism, Medical Knowledge, Quality Improvement

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Didactic

Program Materials Program Evaluations

Event Timeline
01:00 PM - 02:00 PM PDT	Speaker	Safe and Appropriate Opioid Prescribing in Neurology Varun Sreenivasan, MD
02:00 PM - 03:00 PM PDT	Speaker	Medical Treatment of Neuropathic Pain Nicholas J. Silvestri, MD, FAAN

Faculty Disclosures
Nicholas J. Silvestri, MD, FAAN	Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for argenx. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Regeneron. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunovant. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for argenx. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. The institution of an immediate family member of Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda. Dr. Silvestri has received publishing royalties from a publication relating to health care.
Varun Sreenivasan, MD	The institution of Dr. Sreenivasan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ITF therapeutics.

��ɫ��

��ɫ��